狼疮性肾炎治疗的变革:综述
本综述讨论增殖性和膜性狼疮性肾炎的当前及新兴治疗,聚焦靶向发病机制的策略。糖皮质激素联合细胞毒药物或吗替麦考酚酯(MMF)仍是标准治疗,靶向B细胞(如贝利尤单抗、奥妥珠单抗)和T细胞(如伏环孢素)的新药已证实作为附加治疗有效。补体和细胞因子抑制剂等新疗法正在临床前和临床试验中评估,诱导与维持治疗的界限日益模糊。
要点
- 糖皮质激素联合细胞毒药物或MMF仍是狼疮性肾炎标准治疗。
- 贝利尤单抗、奥妥珠单抗和伏环孢素作为附加治疗已证实有效。
- 补体和细胞因子抑制剂等新疗法正在临床试验中评估。
核心结论
- 糖皮质激素联合细胞毒药物或MMF仍是狼疮性肾炎标准治疗,靶向B细胞和T细胞的新药已证实作为附加治疗有效。
研究设计与样本
- 综述,讨论增殖性和膜性狼疮性肾炎的当前及新兴治疗。
主要发现
- 狼疮性肾炎影响高达60%的系统性红斑狼疮患者。
- 靶向B细胞(如贝利尤单抗和奥妥珠单抗)和T细胞(如伏环孢素)的新药已证实作为附加治疗有效。
- 补体和细胞因子抑制剂等新疗法正在临床前和临床试验中评估。
临床怎么用
- 早期诊断和治疗对保护肾功能至关重要。
- 针对不同免疫学和病理学特征的个性化治疗策略有望改变疾病管理。
- 减少长期疾病和药物毒性以改善缓解率和复发率的新策略正在出现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic lupus erythematosus (SLE) is a chronic, multiorgan autoimmune disease, with lupus nephritis (LN) affecting up to 60% of patients. Early diagnosis and treatment are critical for preserving kidney function. Advances in understanding the immunopathogenesis of LN are driving the development of personalized treatment strategies that hold promise for transforming disease management through interventions targeting distinct immunologic and histopathologic features. In this review, we discuss current and emerging therapies for proliferative and membranous LN with a focus on strategies targeting underlying mechanisms of disease in LN. Glucocorticoids with cytotoxic agents or mycophenolate mofetil (MMF) remain the standard of care, but newer therapies targeting B cells (eg, belimumab and obinutuzumab) and T cells (eg, voclosporin) have proven efficacy as add-on treatments. Novel therapies such as complement and cytokine inhibitors are being evaluated in preclinical and clinical trials. Although maintenance therapy with MMF remains the standard, the distinction between sequential induction and maintenance therapy has become increasingly blurred, and new strategies to reduce long-term disease and pharmacologic toxicity to improve remission and relapse rates are emerging.
引用
- Desai NB, Gashti C, Whittier WL, et al. "A Change Is Gonna Come" to Treatment of Lupus Nephritis: A Review. Am J Kidney Dis. 2025. PMID: 41238160. doi:10.1053/j.ajkd.2025.08.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。